Skip to main content
Premium Trial:

Request an Annual Quote

Innovation Philadelphia Funds Acuity and MacroArray

NEW YORK, Sept. 3 (GenomeWeb News)- Innovation Philadelphia, will invest in Acuity Pharmaceuticals and MacroArray Technologies through its Economic Stimulus Fund, the public-private partnership said Tuesday. The amount of each investment was not immediately disclosed.

 

The investment helped the Acuity complete pre-clinical studies for its lead compound and file an IND with the FDA for an RNAi therapeutic, said CEO Dale Pfost in a press release.

 

Acuity is an ophthalmic pharmaceutical company concentrated on RNAi therapeutics. Its flagship product is a macular degeneration drug called Cand 5. MacroArray works on the identification of novel tumor markers, and its lead product, PCADM-1, is a prostate cancer diagnostic test.

 

Innovation Philadelphia invests in local research and commercialization efforts. It is supported in part by the City of Philadelphia and the Commonwealth of Pennsylvania.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.